Screener
Novavax NVAX Upfront fee — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Novavax’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001000694-26-000018
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Takeda licensing, royalties, and other revenue | ||||
| Licensing: | ||||
| Upfront fee(1) | — | $18,500 | — | $18,500 |
| Milestones | — | 3,434 | — | 3,434 |
| Royalties | (50) | 5,000 | 611 | 5,000 |
| Support services | 265 | 278 | 339 | 278 |
| Tota Total Takeda licensing, royalties, and other revenue | $215 | $27,212 | $950 | $27,212 |
Item 1. Consolidated Financial Statements
FAQ
- What is Novavax's upfront fee — total revenue?
- Novavax (NVAX) reported upfront fee — total revenue of $0 in Q2 2026.
- How has Novavax's upfront fee — total revenue changed year-over-year?
- Novavax's upfront fee — total revenue decreased by 100.0% year-over-year, from $18.5M to $0.
- What does upfront fee — total revenue mean?
- This metric represents the total revenue recognized from non-refundable upfront payments received from licensing agreements, collaborations, or research partnerships. It reflects the initial cash inflows associated with granting access to proprietary vaccine technology or intellectual property before the achievement of specific development or commercial milestones. Monitoring this figure helps investors assess the company's ability to monetize its research pipeline and secure early-stage capital through strategic industry partnerships.
Ask your AI about Novavax's upfront fee — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude